The Centers for Disease Control and Prevention (CDC) has provided an update in the federal agency’s Morbidity and Mortality Weekly Report (MMWR) on February 19, 2021, regarding the first month of COVID-19 vaccine safety monitoring in the US from December 14, 2020 through January 13, 2021. The report covers the two COVID-19 vaccines, developed by Pfizer BioNTech […]
Covid-19 and Lyme Disease
We have assembled useful articles to help guide you and your loved ones as we enter the “new normal”.
Please stay safe – we are all in this together!
Adaptive Phage Therapeutics (APT) announced the US Food and Drug Administration (FDA) clearance of the Expanded Access IND for PhageBank™ treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus in COVID-19 patients. APT’s PhageBank™ therapy has been used to treat 9 COVID-19 patients in South Texas with co-infections due to multi-drug resistant Acinetobacter baumannii […]
Johns Hopkins Lyme Disease Research Center’s recently released Winter 2021 Newsletter addresses the confusing new IDSA guidelines, calls attention to the similarities between common COVID-19 long hauler symptoms and persistent Lyme disease, as well as provides insights to significant advances made by their Lyme disease clinical research program, despite challenges brought by the COVID-19 pandemic.
On January 14, 2021, The National Institute of Health (NIH) COVID-19 Treatment Guidelines Panel issued a change in position and are no longer recommending “against” the use of ivermectin for the treatment of COVID-19. This “permission” was issued 8 days after Drs. Paul Marik and Pierre Kory, founding members of the Front Line Covid-19 Critical […]
According to “TrialSite News” on January 21, “Apparently, a judge just ordered the Millard Fillmore Suburban Hospital to allow an 80-year old woman to be treated with Ivermectin. A New York Supreme Court judge ordered hospital to allow her to be treated with Ivermectin for COVID-19. Ivermectin, which had been administered in the ICU with […]
Peter A. McCullough, M.D., M.P.H., Vice Chief of Internal Medicine, Baylor University Medical Center, et al. published an article in the American Journal of Medicine, August 2020: “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection.” The authors have proposed an algorithm based on age and comorbidities that allows for a large proportion to be monitored and treated at home during self-isolation with the aim of reducing the risks of hospitalization and death.
The Lyme Disease Association thanks Congressman Chris Smith and Dr. Richard Horowitz for their valiant efforts to help a chronic Lyme disease patient hospitalized with COVID-19. The following Blog, posted on his Facebook, is reprinted with permission from Dr. Richard Horowitz. The LDA applauds these two courageous individuals trying to buck the system to save a life.
The Lyme Disease Association (LDA) is providing you with this updated November 2, 2020, COVID-19 protocol developed by the Chief of Pulmonary and Critical Care Medicine, EVMS. The EVMS Medical continually updates this guideline as new information emerges, primarily to provide new information to physicians. This information is provided by LDA for informational purposes […]
A study published in the journal Diagnostic Microbiology and Infectious Disease addresses the observed negative effects of the COVID-19 pandemic on the timely diagnosis of tick-borne infections (TBD) in three adult patients.
American insurer Colonial Life is offering a new critical illness plan with optional rider that offers a lump sum benefit for hospitalization for treatment of COVID-19 and over 12 other infectious diseases, such as Lyme disease, antibiotic-resistant bacteria, Legionnaires’ disease, meningitis, and sepsis. For the critical illness plan’s Lyme disease coverage: the date of Lyme […]